Light therapy and lecanemab for mild Alzheimer's
Part of Brain & nervous system, Mental health clinical trials.
This trial tests whether a special near-infrared light device, combined with the medication lecanemab, can help people with mild Alzheimer's disease. It aims to see if the light therapy can slow down memory loss and improve daily function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 90 years old.
- You have a diagnosis of probable Alzheimer's disease (mild stage) confirmed by your doctor.
- A special brain scan (amyloid PET) shows amyloid buildup in your brain.
- You score at least 15 on a standard memory and thinking test (MMSE).
- You have a caregiver who spends at least 1 hour daily with you and can help with the light therapy device.
- You do not have two copies of the APOE ε4 gene, and you are not taking blood thinners.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called lecanemab for people with early onset familial Alzheimer's disease. It aims to see if the drug can help slow cognitive decline in those with confirmed signs of Alzheimer's in their brain.
This study tests whether shining a special near-infrared light on the head can help people with mild to moderate Alzheimer's disease. The light is thought to improve brain cell function and reduce damage.
This study tests how lecanemab works in people with early Alzheimer’s, including those with mild dementia or mild memory problems. It aims to see if the drug can help clear brain plaques and slow down symptoms.
This study looks at how well lecanemab works for people with early Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
This study tests a drug called Lecanemab in people with early Alzheimer's. It uses a blood test to see how well the drug works. You may qualify if you have mild Alzheimer's or mild cognitive impairment due to Alzheimer's and have a positive amyloid test.
This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.